In sum, while addition of the PD1-CD28 CSRs did not increase redirected killing of tumor cells by MSLN TRuC-T cells, we observed a higher cytokine secretion and increased TCR signaling in cells bearing the CSRs. This evidence concerns the gene CD28 and neoplasm.